Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Walewski, Jan
102  Ergebnisse:
OpenAccess-Volltexte X
Personensuche X
?
1

Carfilzomib, lenalidomide, and dexamethasone or lenalidomid..:

Dytfeld, Dominik ; Wróbel, Tomasz ; Jamroziak, Krzysztof...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10337122/.  , 2023
Link: http://www.ncbi.nlm.nih...
 
?
2

PB2358: PHASE 1-2 STUDY OF THE SAFETY, PK, PD, AND PRELIMIN..:

Shortt, Jake ; Poligone, Brian ; Ribrag, Vincent...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429443/.  , 2023
Link: http://www.ncbi.nlm.nih...
 
?
3

New molecular targets in Hodgkin and Reed-Sternberg cells:

Sadaf, Hummaira ; Ambroziak, Maciej ; Binkowski, Robert...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10230546/.  , 2023
Link: http://www.ncbi.nlm.nih...
 
?
4

Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory ..:

Zinzani, Pier Luigi ; Trněný, Marek ; Ribrag, Vincent...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10433033/.  , 2023
Link: http://www.ncbi.nlm.nih...
 
?
5

P1115: ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY DI..:

Walewski, Jan ; Min Kim, Tae ; Cho, Seok-Goo...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431082/.  , 2023
Link: http://www.ncbi.nlm.nih...
 
?
6

Anti-CD20–atezolizumab–polatuzumab vedotin in relapsed/refr..:

Topp, Max S ; Eradat, Herbert ; Florschütz, Axel...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9931830/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
?
7

High-Dose Cytarabine and Autologous Stem-Cell Transplantati..:

Hermine, Olivier ; Jiang, Linmiao ; Walewski, Jan...
boreal:270042.  , 2022
Link: http://hdl.handle.net/20..
 
?
8

Tackling Mantle Cell Lymphoma in Europe:

Horgan, Denis ; Walewski, Jan ; Aurer, Igor...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9498856/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
?
9

Ibrutinib plus Bendamustine and Rituximab in Untreated Mant..:

Wang, Michael L ; Jurczak, Wojciech ; Jerkeman, Mats...
boreal:282153.  , 2022
Link: http://hdl.handle.net/20..
 
?
10

Ibrutinib plus Bendamustine and Rituximab in Untreated Mant..:

Wang, Michael L ; Jurczak, Wojciech ; Jerkeman, Mats...
boreal:282153.  , 2022
Link: http://hdl.handle.net/20..
 
?
11

High efficacy of intensive immunochemotherapy for primary m..:

Romejko-Jarosinska, Joanna ; Ostrowska, Beata ; Dabrowska-Iwanicka, Anna...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9217998/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
?
12

High-Dose Cytarabine and Autologous Stem-Cell Transplantati..:

Hermine, Olivier ; Jiang, Linmiao ; Walewski, Jan...
boreal:270042.  , 2022
Link: http://hdl.handle.net/20..
 
?
13

Prospective subgroup analyses of the randomized MCL-002 (SP..:

Arcaini, Luca ; Lamy, Thierry ; Walewski, Jan...
10.1111/bjh.15025.  , 2021
Link: https://hdl.handle.net/2..
 
?
14

Response to brentuximab vedotin versus physician's choice b..:

Kim, Youn H ; Prince, H. Miles ; Whittaker, Sean...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9347228/.  , 2021
Link: http://www.ncbi.nlm.nih...
 
?
15

Response to brentuximab vedotin versus physician's choice b..:

Kim, Youn H ; Prince, H Miles ; Whittaker, Sean...
qt5zg5n6x3.  , 2021
Link: https://escholarship.org..
 
1-15